<DOC>
	<DOC>NCT02665910</DOC>
	<brief_summary>Condition: Rheumatoid Arthritis Intervention: Drug: SHR0302; Drug: SHR0302 placebo comparator Phase: Phase 1 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized</brief_summary>
	<brief_title>Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Male or female subjects who are 18~70 years of age on the day of signing informed consent, Have a diagnosis of RA meeting the 1987 ACR/EULAR criteria of RA and ACR functional class IIII, Body mass index (BMI = weight/height squared (kg/m2)) within the range of 19 to 30, Have agreed to not use any anti rheumatic drug except for study drugs during the study period. Current therapy with any disease modifying antirheumatic drug (DMARD), with the exception of Methotrexate (MTX), Leflunomide, sulfasalazine, antimalarials, gold preparations, penicillamine, which must have discontinued for a period of at least 7 t1/2s prior to dosing, Previous RA treatment with DMARDs or drugs with strong immunosuppressive effect in 3 months prior to dosing (12 months for rituximab or other B cell depleting agents), Previous therapy with NSAIDs or oral glucocorticoids in 2 weeks before dosing, Any parenteral (intramuscular or intravenous injection) or intraarticular corticosteroids therapy in 4 weeks before dosing, Previous treatment with interferons in 4 weeks before dosing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>